Product Code: DMKC0160959
Wearables encompass the growing range of gadgets that can be attached to the body to measure certain physiological parameters. They are rapidly being adopted in healthcare, as part of a broader health IT revolution, with significant consequences for pharma in both the economics and execution of R&D. There are already an estimated 300 trials underway involving wearables, according to National Institutes of Health data reported in late
2015. Wearables' most immediate potential is in chronic diseases.
This report addresses the following questions:
- What are wearables and how are they impacting pharma?
- Who is developing wearables and what partnerships have pharma companies forged as they venture into this new domain?
- What are the key drivers and resistors to wearables' use in healthcare?
- How has pharma experimented with wearables so far and what are the key takeaways for drug developers?
- What impact have wearables had on pharma R&D so far?
- How will wearables fit within the pharma business model and where is there most potential to generate return on investment from wearables?
TABLE OF CONTENTS
- 1. What are wearables, and why should pharma care?
- 2. Wearables makers: pharma partners or competitors?
- 3. Wearables' early impact in R&D and beyond
- 4. Drivers and resistors of wearables in healthcare
- 5. Case studies involve a range of players, devices, and therapy areas
- 6. Wearables are part of digital health investments
WHAT ARE WEARABLES, AND WHY SHOULD PHARMA CARE?
- 7. Wellness and medicine: blurring boundaries
- 8. Enabling patient centricity; lowering costs
- 9. Bibliography
WEARABLES MAKERS: PHARMA PARTNERS OR COMPETITORS?
- 10. Who is making wearables?
- 11. Fostering and funding digital health innovation
- 12. Bibliography
- WEARABLES' EARLY IMPACT IN R&D AND BEYOND
- 13. Most wearables trials to date have been feasibility studies
- 14. Bibliography
DRIVERS AND RESISTORS OF WEARABLES IN HEALTHCARE
- 15. Drivers
- 16. Resistors
- 17. Bibliography
WEARABLES CASE STUDIES
- 18. Wearables are used along the value chain and across stakeholders
- 19. Biogen-Google: uncovering the course of multiple sclerosis
- 20. Novartis-Qualcomm: building the foundations for mobile trials
- 21. Novartis-Microsoft: measuring multiple sclerosis
- 22. UCB-MC10: improving diagnosis and treatment of Parkinson's disease
- 23. Johns Hopkins-Apple: using Apple Watch to predict seizures
- 24. UnitedHealthcare-Qualcomm: paying for steps
- 25. Medibio-Medtronic: diagnosing depression
- 26. Google (Verily)-Dexcom: stick-on glucose monitors for diabetes
- 27. Otsuka-Proteus Digital Health: digital medicines may improve outcomes but first must pass regulatory muster
- 28. Bibliography
WEARABLES ARE PART OF DIGITAL HEALTH INVESTMENTS
- 29. Unquantified investments
- 30. Efficacy gains expected
- 31. Who will pay for wearables in healthcare?
- 32. The technological future
- 33. Bibliography
- 34. About the author
- 35. Scope
- 36. Methodology